Praluent market seen growing as obesity and personalized medicine rise

The Business Research Company says the global Praluent market is set for continued growth through 2035, driven by rising obesity, broader use of personalized medicine and expanding cardiovascular care. North America leads the market now, while Asia-Pacific is expected to grow fastest.

Why it matters: - The Praluent market is tied to two of the biggest forces in cardiovascular care: rising cholesterol-related disease and broader use of targeted therapies. - Growing demand could expand access to PCSK9 inhibitor treatment for patients who need more aggressive LDL cholesterol lowering. - The market outlook also signals where payer support, specialist care and preventive cardiology may be headed next.

What happened: - The Business Research Company published The Praluent Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the Praluent market is changing as cardiovascular treatment strategies and health concerns evolve. - The company says market growth through 2026 and beyond is being shaped by rising hypercholesterolemia, limits of statin-only treatment, broader cardiovascular risk screening, more biologic cardiovascular drugs and better access to specialist cardiology care. - A free sample of the report is available here. - The full report is available here.

The details: - Praluent is a monoclonal antibody designed to lower LDL cholesterol. - The drug is prescribed for adults with primary hypercholesterolemia or mixed dyslipidemia. - Praluent is also used to reduce cardiovascular risk in patients with existing heart conditions. - The report says future growth will be supported by more aggressive lipid-lowering strategies, wider use in secondary prevention, value-based cardiovascular care models, expanding payer support for PCSK9 inhibitors and greater awareness of cardiovascular risk reduction. - Forecast-period trends include broader use of PCSK9 inhibitors in lipid management, more use in high-risk cardiovascular patients, combination therapy with statins, expansion of preventive cardiology programs and stronger long-term LDL management. - Rising obesity is a key growth driver. - The report defines obesity as a Body Mass Index of 30 or greater. - The report links the global rise in obesity to more ultra-processed food consumption, sedentary lifestyles and economic factors that favor unhealthy diets. - Praluent supports obesity-related dyslipidemia by inhibiting PCSK9, which helps the liver clear LDL cholesterol from the bloodstream. - A May 2024 UK Office for Health Improvement and Disparities estimate said 64.0% of adults in England were overweight or obese in 2022–2023, including 26.2% classified as obese. - Personalized medicine is another major demand driver. - The report says clinicians are increasingly matching therapies to genetic and biomarker profiles to improve outcomes. - BioSpace reported in February 2025 that the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. - In 2025, North America held the largest share of the global Praluent market. - The Asia-Pacific region is projected to be the fastest-growing market during the forecast period. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - The report frames Praluent as part of a wider shift toward individualized, risk-based cardiovascular treatment rather than one-size-fits-all statin therapy. - Obesity and personalized medicine are being presented as connected tailwinds: more at-risk patients and more targeted prescribing can both lift demand. - The regional split suggests mature markets will remain important revenue centers, while growth may increasingly come from healthcare expansion in emerging markets.

What's next: - The report expects faster uptake of Praluent in secondary prevention and high-risk patient groups. - Wider payer support for PCSK9 inhibitors could make access easier if coverage expands. - Preventive cardiology programs and long-term LDL management are likely to stay central to the market’s direction. - The Business Research Company says its 2026 market reports include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics and updated trend analysis.

The bottom line: - Praluent’s market outlook is improving because the clinical need for intensive cholesterol control keeps rising, and the treatment landscape is moving toward more personalized cardiovascular care.